1. Drug combination, including one formula (1) compound (as described in this description) or acceptable salt on one drug and one quinase inhibitor selected from at least one BRAF inhibitor or MEK inhibitor for treatment Melanoma. Methods of treatment for melanoma, including treatment of subjects requiring an effective number of CDK inhibitors and at least an effective number of anticancer agentsSelected from BRAF inhibitors or MEK inhibitors 1. Characteristic 1: effective treatment quantity of a CDK inhibitor (cyclohexylase) selected from formula compound (1) or a salt acceptable on a druga. AR is phenyl and is replaced by one or two selected alternatives of chlorine and trifluoroide； Combined with at least one effective therapeutic amount of an anticancer agent selected from a BRAF inhibitor (SERINA Trenin B-Raf, quinasa protetica) or a MEK inhibitor (quinasa protetica, trichloroactive pentabromodiphenyl ether),A drug developed for the treatment of melanoma. 13. Claim 3: to be used in accordance with the provisions of claim 2, wherein the CDK inhibitor is a (+ - trans-2 - (2-chloro-4-trifluoroethane) - 5, 7-dihydroxi-8 - (2-hydroxymethyl-1-meth-pirrolidin-3-il) - chromium-4-chloroone-hydrate (as a compound A or voruciclib).Combinación farmacéutica que comprende un inhibidor de quinasa dependiente de ciclina (CDK) representado por un compuesto de la fórmula (1) (como se describe en la presente) o una sal farmacéuticamente aceptable del mismo y por lo menos un agente anticancerígeno seleccionado de un inhibidor BRAF o un inhibidor MEK, para uso en el tratamiento del melanoma. Método para el tratamiento del melanoma que comprende administrar a un sujeto que necesite una cantidad terapéuticamente efectiva de un inhibidor CDK y una cantidad terapéuticamente efectiva de por lo menos un agente anticancerígeno seleccionado de un inhibidor BRAF o un inhibidor MEK. Reivindicación 1: Uso de una cantidad terapéuticamente efectiva de un inhibidor CDK (quinasa dependiente de ci
